Stock Insider Trading (from SEC Form 4)
ATRS / Antares Pharma, Inc. insiders include Deerfield Mgmt L.P. (), APPLE ROBERT F (President & CEO), Stacey Jennifer Evans (SVP, General Counsel & Secty), JACOB LEONARD S, and DEERFIELD MANAGEMENT CO (), ROCHE ROBERT P JR, GARRITY THOMAS J Powell Fred M (Senior Vice President & CFO), Fickenscher James E (Senior Vice President & CFO), Deerfield International Master Fund, L.P. (), GRAHAM PETER J (SVP General Counsel, Secretary), Deerfield Special Situations Fund, L.P. (), HOBBS EAMONN P (President & CEO), GONELLA JACQUES, SAMSON MARVIN, Flynn James E (), DEERFIELD PARTNERS, L.P. (), GUETH ANTON, .
Antares Pharma, Inc. insider trades are found here. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Job titles are listed as of the filing and may not be current. Click the link icon to see the full transaction history.
Stop missing out on important events!
|Tran Value||Post Value||Percent
JACOB LEONARD S
GARRITY THOMAS J
Powell Fred M
APPLE ROBERT F
GRAHAM PETER J
Fickenscher James E
ROCHE ROBERT P JR
Flynn James E
Deerfield Mgmt L.P.
DEERFIELD MANAGEMENT CO
DEERFIELD PARTNERS, L.P.
Deerfield International Master Fund, L.P.
Deerfield Special Situations Fund, L.P.
HOBBS EAMONN P
Stacey Jennifer Evans
- Open market or private purchase of non-derivative or derivative security
- Open market or private sale of non-derivative or derivative security
- Grant, award, or other acquisition of securities from the company (such as an option)
- Conversion of derivative
- Sale or transfer of securities back to the company
- Payment of exercise price or tax liability using portion of securities received from the company
- Gift of securities by or to the insider
- Equity swaps and similar hedging transactions
- Exercise or conversion of derivative security received from the company (such as an option)
- A transaction voluntarily reported on Form 4
- Other (accompanied by a footnote describing the transaction)
ATRS : Antares Pharma Stock Analysis and Research Report
Antares Pharma, Inc. is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its strategy is to identify new or existing approved drug formulations and apply its drug delivery technology to enhance the drug compounds and delivery methods. The company develop, manufacture and commercialize, for itself or with partners, novel therapeutic products using its advanced drug delivery systems that are designed to help improve safety and efficacy, reduce side effects, and enhance patient comfort and adherence. Its subcutaneous injection technology platforms include the VIBEX® pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-dose pen injectors for use with standard cartridges. Antares Pharma has a portfolio of proprietary and partnered pro...
Related News Stories
The market has staged a huge bounce-back rally this week after two weeks of brutal declines. (126-3)
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares are skyrocketing Thursday as the company received regulatory approval for one of its treatments. (45-0)
AMAG Pharmaceuticals Inc. (NASDAQ: AMAG) saw its shares skyrocket early on Thursday after the company announced that it received an FDA approval. Specifically, the company said that the FDA approved its supplemental New Drug Application (NDA) for Makena, which was designed as a treatment to reduce the risk of preterm birth in women who are pregnant with one baby and who spontaneously delivered one preterm baby in the past. (45-0)
Shares of Antares Pharma Inc. ATRS, -1.49% and Amag Pharmaceuticals AMAG, +1.46% soared in premarket trade Thursday, after Amag said the U.S. Food and Drug Administration has approved their Makena subcutaneous auto injector drug-device combination product, a ready-to-administer treatment to reduce the risk of preterm birth in women who are pregnant with one baby and who spontaneously delivered one preterm baby in the past. (34-0)
But the company is buying those revenues: earnings are down, and the legacy portfolio is collapsing. (35-1)
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (50-0)
Biotech is rising in 2018 but still lags other sectors that will see more direct impacts from the recently passed tax legislation. (685-1)
In my view, three biotech microcaps may yield among the best risk/reward scenarios for investors today. (182-5)
NEW YORK, NY / ACCESSWIRE / November 27, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS) of the December 22, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. (34-1)
NEW YORK, NY / ACCESSWIRE / November 27, 2017, 2017 / The following statement is being issued by Levi & Korsinsky, LLP: (34-1)